Healthcare Industry News: BARACLUDE
News Release - November 14, 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice PresidentsNEW YORK, Nov. 14 (HSMN NewsFeed) -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced that Andrew Bonfield, chief financial officer, and Elliott Sigal, M.D., Ph.D., chief scientific officer, have been appointed executive vice presidents of Bristol-Myers Squibb. They join Lamberto Andreotti, president, Worldwide Pharmaceuticals, as executive vice presidents of the company.
Bonfield will continue to lead Global Finance and Strategic Planning and Issues Management. Dr. Sigal continues his leadership of the Pharmaceutical Research Institute (PRI), the research and development arm of the company.
"Andrew and Elliott have played critical roles in the execution of the corporate strategy," said James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "Andrew has delivered superior oversight of the company's financial and operating performance, and was instrumental in integrating compliance throughout the company with new requirements under the Sarbanes Oxley Act. Under Elliott's leadership, the PRI has delivered eight new product approvals in fewer than four years. This is outstanding performance by any measure."
Previously, Mr. Bonfield served as director of Finance at the BG Group, PLC, an international energy company. Prior to that, he was chief financial officer at SmithKline Beecham -- now GlaxoSmithKline -- responsible for all aspects of the company's finances, including corporate control, operations, finance, tax, strategy and development.
Mr. Bonfield holds a Bachelor of Commerce degree from the University of Natal in Durban, South Africa and is professionally certified as a chartered accountant.
Dr. Sigal has held senior positions in both discovery and development in the PRI, joining the company nearly 10 years ago to start its genomics department. As chief scientific officer, he achieved five new product approvals: ORENCIA®, SPRYCEL®, BARACLUDE®, EMSAM® and ATRIPLA(TM). As senior vice president of clinical development, he secured the approvals of ABILIFY®, ERBITUX® and REYATAZ®.
Dr. Sigal has more than 20 years of combined experience in medicine, research and management. He received his medical degree from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). His research training was received at the Cardiovascular Research Institute at UCSF. Prior to medical school he studied engineering and management at Purdue University where he received a B.S., M.S., and Ph.D.
Mr. Andreotti, executive vice president and president of Worldwide Pharmaceuticals since 2005, leads global pharmaceuticals operations, as well as Technical Operations and Global Marketing at Bristol-Myers Squibb. He joined the company in 1998 as vice president European Oncology and general manager of Italy. In 2000, he was named president, Europe, and in 2002 he became senior vice president, Bristol-Myers Squibb, and president, International. In this role, he also was responsible for Mead Johnson Nutritionals and ConvaTec.
Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
ABILIFY® is a trademark of Otsuka Pharmaceutical Company, Ltd.
Erbitux® is a trademark of ImClone Systems Incorporated
EMSAM® is a trademark of Somerset Pharmaceuticals, Inc.
ATRIPLA(TM) is a trademark of both Bristol-Myers Squibb Co. and Gilead Sciences, Inc.
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.